Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
Identifying and optimizing the Medical Affairs talent pool
Insights from the MAPS New Orleans 2025 roundtable session. The session highlighted the essential talent needs—such as competencies, qualifications, and...